Syndax Pharmaceuticals Reports Strong Q4 & Full Year 2025 Revenue Growth, Advances Pipeline, and Nears Profitability

summarizeSummary

Syndax Pharmaceuticals delivered robust financial results for the fourth quarter and full year 2025, showcasing significant commercial momentum for its key products, Revuforj and Niktimvo. Revuforj net revenue surged 38% quarter-over-quarter to $44.2 million in Q4 2025, while Niktimvo net revenue increased 22% to $56.0 million. The company also reported a reduced net loss for both the quarter and the full year, indicating improving financial health. With $394.1 million in cash and equivalents, Syndax projects a stable operating expense base and expects to reach profitability with its current financial resources and anticipated product revenue. Additionally, the company achieved key pipeline milestones, including completing enrollment in the Phase 2 IPF trial for axatilimab and initiating a pivotal Phase 3 trial for revumenib in newly diagnosed AML, reinforcing its growth trajectory.

check_boxKey Events

• Strong Revenue Growth

  Total revenue for Q4 2025 reached $68.7 million, with Revuforj net revenue increasing 38% quarter-over-quarter to $44.2 million and Niktimvo net revenue growing 22% to $56.0 million. Full year 2025 total revenue was $172.4 million.

• Reduced Net Loss

  The net loss attributable to common stockholders decreased to $68.0 million in Q4 2025 from $94.2 million in Q4 2024, and to $285.4 million for the full year 2025 from $318.8 million in 2024.

• Solid Financial Position & Path to Profitability

  Syndax ended 2025 with $394.1 million in cash, cash equivalents, and short-term investments. The company expects its operating expense base to remain stable and anticipates reaching profitability with current resources and projected revenues.

• Key Pipeline Advancements

  Enrollment was completed in the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF), with topline data expected in Q4 2026. The company also initiated REVEAL-ND, a Phase 3 trial for revumenib in newly diagnosed NPM1m AML.

auto_awesomeAnalysis

Syndax Pharmaceuticals delivered robust financial results for the fourth quarter and full year 2025, showcasing significant commercial momentum for its key products, Revuforj and Niktimvo. Revuforj net revenue surged 38% quarter-over-quarter to $44.2 million in Q4 2025, while Niktimvo net revenue increased 22% to $56.0 million. The company also reported a reduced net loss for both the quarter and the full year, indicating improving financial health. With $394.1 million in cash and equivalents, Syndax projects a stable operating expense base and expects to reach profitability with its current financial resources and anticipated product revenue. Additionally, the company achieved key pipeline milestones, including completing enrollment in the Phase 2 IPF trial for axatilimab and initiating a pivotal Phase 3 trial for revumenib in newly diagnosed AML, reinforcing its growth trajectory.